

7. A mono-HCl salt of the compound of formula (I), as claimed in claim 3, in crystalline form which has an X-ray powder diffraction pattern with specific peaks at about $2\text{-theta} = 12.3, 13.9, 9.3, 23.3, 18.7, 16.0, 24.6, 26.8, 28.0^\circ$.

5 8. A succinate salt of the compound of formula (I), as claimed in claim 4, in crystalline form which has an X-ray powder diffraction pattern with at least three specific peaks at about $2\text{-theta} = 6.5^\circ, 17.7^\circ$ and 14.7° .

9. A succinate salt of the compound of formula (I), as claimed in claim 4, in
10 crystalline form which has an X-ray powder diffraction pattern with specific peaks at about $2\text{-theta} = 6.5, 17.7, 14.7, 9.2, 26.5, 20.2, 13.1, 27.3, 24.0^\circ$.

10. A pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-9, in
15 association with a pharmaceutically-acceptable diluent or carrier.

11. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-9, for use as a medicament.

20 12. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-9, in the manufacture of a medicament for the inhibition of activating mutant EGFR in a warm-blooded animal such as man.

25 ~~13. A method for producing an anti-cancer effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-9.~~

30 ~~1413.~~ A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-9, for use in the treatment of non-small-cell lung cancer.

14. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-9, for use in the treatment of metastatic non-small-cell lung cancer.

15. The compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 14, wherein metastases of the metastatic non-small-cell lung cancer include brain metastases.

16. The compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 14, wherein metastases of the metastatic non-small-cell lung cancer include leptomeningeal metastases.

17. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-9, in combination with an anti-tumour agent selected from:

- (i) an anti-CTLA-4 antibody;
- (ii) 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3*H*-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide or a pharmaceutically acceptable salt thereof;
- (iii) an anti-PD-L1 antibody;
- (iv) 1-[(1*S*)-1-(imidazo[1,2-*a*]pyridin-6-yl)ethyl]-6-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-[1,2,3]triazolo[4,5-*b*]pyrazine or a pharmaceutically acceptable salt thereof;
- (v) an anti-PD-1 antibody; or
- (vi) an OX40 agonist antibody.